Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc.
Subsidiary
Traded as NASDAQ: SCMP
Industry Pharmaceutical
Fate Acquired by Mallinckrodt
Founded 1996
Headquarters Bethesda, Maryland
Products Amitiza
Website sucampo.com

Sucampo Pharmaceuticals, Inc. was a public, American biopharmaceutical company focused on medical applications of a class of ion channel modulators called prostones.[1][2] A subsidiary of Mallinckrodt plc closed its acquisition of the company on February 13, 2018.[3]

Products

Sucampo has two marketed products, Amitiza and Rescula.[4] As of 2014, Takeda distributes this drug globally except for in Japan and China.[5]

Corporate governance

The company's chief financial officer, as of 2014, was Cary J. Claiborne.[6]

References

  1. ↑ "SCMP—News and Analysis—Sucampo Pharmaceuticals, Inc". Seeking Alpha. Company description. Retrieved 1 January 2015.
  2. ↑ Brewer, Jim (31 December 2014). "Sucampo Pharmaceuticals Hits New 12-Month High at $14.90 (SCMP)". WKRB News. WKRB.
  3. ↑ http://www.mallinckrodt.com/about/news-and-media/2332127
  4. ↑ Staff (5 December 2014). "Sucampo Pharmaceuticals (SCMP): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report".
  5. ↑ House, Douglas W. (31 December 2014). "Canada accepts Sucampo's NDS for constipation med". Seeking Alpha.
  6. ↑ Pearson, Nolan (30 December 2014). "Maxim Group Raises Sucampo Pharmaceuticals Price Target to $15.00". WKRB News. WKRB.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.